Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Price Target at $37.10

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been given an average recommendation of “Moderate Buy” by the ten ratings firms that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $37.10.

A number of brokerages recently issued reports on STOK. Loop Capital set a $35.00 target price on Stoke Therapeutics in a research report on Monday, January 5th. UBS Group set a $50.00 target price on shares of Stoke Therapeutics in a report on Monday, December 15th. Needham & Company LLC raised their price target on Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, October 10th. Chardan Capital boosted their price target on Stoke Therapeutics from $24.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, January 5th. Finally, JPMorgan Chase & Co. upped their price objective on Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a research note on Monday, November 3rd.

Insider Transactions at Stoke Therapeutics

In related news, General Counsel Jonathan Allan sold 3,978 shares of the stock in a transaction on Monday, December 8th. The stock was sold at an average price of $32.28, for a total transaction of $128,409.84. Following the completion of the sale, the general counsel directly owned 11,831 shares of the company’s stock, valued at $381,904.68. This trade represents a 25.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Edward M. Md Kaye sold 13,430 shares of Stoke Therapeutics stock in a transaction on Monday, December 8th. The shares were sold at an average price of $32.27, for a total transaction of $433,386.10. Following the completion of the transaction, the director owned 49,124 shares in the company, valued at approximately $1,585,231.48. This trade represents a 21.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 104,705 shares of company stock worth $3,070,910 over the last 90 days. 9.50% of the stock is currently owned by insiders.

Institutional Trading of Stoke Therapeutics

Several hedge funds have recently modified their holdings of STOK. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Stoke Therapeutics by 5.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock worth $162,000 after acquiring an additional 1,149 shares during the period. CANADA LIFE ASSURANCE Co lifted its holdings in Stoke Therapeutics by 12.3% in the third quarter. CANADA LIFE ASSURANCE Co now owns 11,978 shares of the company’s stock valued at $296,000 after acquiring an additional 1,313 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after purchasing an additional 1,668 shares in the last quarter. Generali Investments Management Co LLC acquired a new position in shares of Stoke Therapeutics during the 3rd quarter worth $41,000. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Stoke Therapeutics by 14.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,099 shares of the company’s stock worth $171,000 after purchasing an additional 1,862 shares during the period.

Stoke Therapeutics Trading Down 2.0%

Shares of NASDAQ STOK opened at $28.70 on Friday. The stock has a market cap of $1.64 billion, a P/E ratio of 42.84 and a beta of 1.10. The business’s fifty day simple moving average is $30.76 and its 200-day simple moving average is $24.46. Stoke Therapeutics has a 12-month low of $5.35 and a 12-month high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.11). The company had revenue of $10.63 million for the quarter, compared to analyst estimates of $6.06 million. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%. On average, equities analysts forecast that Stoke Therapeutics will post -2.01 EPS for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.